Journal of Pharmaceutical Sciences 1998-03-01

Determination of binding conformations of drugs to human serum albumin by transferred nuclear overhauser effect measurements and conformational analyses using high-temperature molecular dynamics calculations.

Y Matsushita, H Gouda, H Tsujishita, S Hirono

Index: J. Pharm. Sci. 87 , 379-386, (1998)

Full Text: HTML

Abstract

The binding conformations of oxyphenbutazone (OXY), Nepsilon-dansyl-L-lysine (DNS-LYS), and furosemide (FU) to human serum albumin (HSA) have been investigated by molecular dynamics (MD) calculations and transferred nuclear Overhauser effect (TRNOE) measurements. We have combined distance information obtained from the Conformational Analyzer with Molecular Dynamics And Sampling (CAMDAS) calculation and experimental NOE spectroscopy measurements to determine a "binding conformation" for each drug which binds to site I of HSA. For OXY, only one conformer (conf9) among the conformer set generated by MD calculation satisfied the distance restraint conditions obtained from TRNOE measurements. For DNS-LYS and FU, 17 and 5 conformers satisfied distance restraint conditions, respectively. The structure of conf9 of OXY was taken as a "template" to choose binding conformers for DNS-LYS and FU. By fitting the "template" to the 17 conformers of DNS-LYS and 5 conformers of FU, we could efficiently obtain one binding conformer for DNS-LYS (conf144) and FU (conf26). It is suggested from the feature of the binding conformation that the three-dimensional location of a hydrophobic aromatic ring, alkyl chain, and electronegative functional group is important for binding to site I of HSA. This method, which combines MD calculations and NOE information, is thought to be effective for determining the binding conformation of drugs to HSA.


Related Compounds

Related Articles:

Bone marrow depression due to mianserin, phenylbutazone, oxyphenbutazone, and chloramphenicol--Part I.

1986-07-01

[Adverse Drug React. Acute Poisoning Rev. 5(2) , 97-136, (1986)]

Bone marrow depression due to mianserin, phenylbutazone, oxyphenbutazone, and chloramphenicol--Part II.

1986-10-01

[Adverse Drug React. Acute Poisoning Rev. 5(3) , 181-96, (1986)]

Disposition and tolerance of suxibuzone in horses.

1999-09-01

[Equine Vet. J. 31(5) , 411-6, (1999)]

Pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in miniature donkeys.

2001-05-01

[Am. J. Vet. Res. 62(5) , 673-5, (2001)]

Screening, quantification, and confirmation of phenylbutazone and oxyphenbutazone in equine plasma by liquid chromatography-tandem mass spectrometry.

2009-01-01

[J. Anal. Toxicol. 33(1) , 41-50, (2009)]

More Articles...